GHRP-2 Offers Safe and Rapid Diagnostic Test for Growth Hormone Deficiency in Children
Background
The Insulin Tolerance Test (ITT) has long been considered the gold standard for diagnosing Growth Hormone Deficiency (GHD), a condition where the body doesn't produce enough growth hormone, leading to stunted growth in children. However, the ITT can be risky and is contraindicated in some patients due to the risk of severe hypoglycemia. While GH-Releasing Peptide-2 (GHRP-2), a synthetic peptide that stimulates the release of growth hormone, has been validated as a safe and reliable diagnostic test for severe GHD in adults, its efficacy and safety specifically for diagnosing GHD in children remained less explored.
Results
The study revealed a highly favorable correlation between the peak GH values elicited by GHRP-2 and those obtained from the established Insulin Tolerance Test (ITT), indicated by a Spearman correlation coefficient with P<0.0001. Crucially, children diagnosed with Growth Hormone Deficiency (GHD) exhibited significantly lower peak GH concentrations (median: 3.39 µg/l) compared to children without GHD (25.10 µg/l), a difference that was also highly statistically significant (p<0001). This represents an approximate 7.4-fold lower median peak GH response in GHD children. Peak GH concentrations were significantly (p<0.0001) lower in children with Growth Hormone Deficiency (GHD) (median: 3.39 µg/l) compared to those without GHD (25.10 µg/l), demonstrating a clear diagnostic distinction. Further analysis of sensitivity-specificity curves identified a serum GH concentration of 15 µg/l as the optimal diagnostic cutoff point, where sensitivity and specificity for GHD diagnosis intersected. The GHRP-2 test was also noted for its safety and efficiency, requiring one hour or less to complete.
Why It Matters
This research highlights the significant potential of GH-Releasing Peptide-2 (GHRP-2) as a safe, rapid, and reliable diagnostic tool for Growth Hormone Deficiency (GHD) in children. Given that the traditional Insulin Tolerance Test (ITT), while reliable, carries contraindications and risks for certain pediatric patients, GHRP-2 offers a crucial and less invasive alternative. The findings suggest that the GHRP-2 test could become a widely adopted standard for diagnosing GHD in pediatric populations, potentially leading to earlier, safer, and more accessible interventions. Future steps would likely involve larger, multi-center clinical trials to further validate these findings and establish standardized protocols for widespread clinical use.